Table 1 Clinical characteristics of the breast cancer patients included in this study.
From: Circulating tumor cells detection in tumor draining vein of breast cancer patients
All patients, n (%) | Primary surgery patients, n (%) | NAC patients, n (%) | |
|---|---|---|---|
Total patients | 36 | 13 | 23 |
Age, median (range), years | 53 (35–81) | 60 (44–81) | 51 (35–73) |
Tumor stage | |||
T0 | 1 (3) | 0 (0) | 1 (4) |
T1 | 10 (28) | 7 (54) | 3 (13) |
T2 | 19 (53) | 6 (46) | 13 (53) |
T3 | 4 (11) | 0 (0) | 4 (17) |
T4 | 1 (3) | 0 (0) | 1 (4) |
Lymph node status | |||
1–3 lymph nodes | 24 (67) | 8 (62) | 16 (70) |
>3 lymph nodes | 12 (33) | 5 (38) | 7 (30) |
Estrogen receptor | |||
Positive | 25 (69) | 11 (85) | 14 (61) |
Negative | 11 (31) | 2 (15) | 9 (39) |
Progesterone receptor | |||
Positive | 19 (53) | 9 (69) | 10 (43) |
Negative | 17 (47) | 4 (31) | 13 (57) |
HER2 | |||
Positive | 10 (28) | 1 (8) | 9 (39) |
Negative | 26 (72) | 12 (92) | 14 (61) |
Histologic tumor grade | |||
Grade 1 | 3 (8) | 2 (15) | 1 (4) |
Grade 2 | 18 (50) | 9 (69) | 9 (39) |
Grade 3 | 14 (39) | 2 (15) | 12 (52) |
NA | 1 (3) | 0 (0) | 1 (4) |
Neoadjuvant/adjuvant chemotherapy regimen | |||
AC-T | 21 (58) | 7 (54) | 14 (61) |
AC-T + H | 7 (19) | 0 (0) | 7 (30) |
Others | 5 (14) | 3 (23) | 2 (9) |
None | 3 (8) | 3 (23) | 0 (0) |
Pathologic complete response | |||
Yes | — | — | 8 (35) |
No | — | — | 15 (65) |
